Tirzepatide for Managing Overweight and Obesity ( NICE guideline summary )

Title: Tirzepatide for Managing Overweight and Obesity
Publication Date: December 23, 2024

The groundbreaking dual-action mechanism of tirzepatide is reshaping how we approach overweight and obesity management. Highlighted in the latest NICE guidance, tirzepatide functions as both a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This innovative therapy not only aids in weight loss but also improves glycemic control by targeting metabolic pathways within the gut-brain axis. By slowing gastric emptying, curbing appetite, and enhancing insulin sensitivity, tirzepatide emerges as a powerful tool in addressing two critical health challenges: obesity and its related metabolic disorders.

Mechanism of Action (MOA)

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

• It mimics the actions of GIP and GLP-1 to regulate appetite, enhance insulin sensitivity, and promote weight loss by influencing metabolic pathways in the gut-brain axis.
• The drug slows gastric emptying, reduces caloric intake, and improves glycemic control.
• 
  

Clinical Evidence

• SURMOUNT Trials: Participants achieved 10-20% total body weight loss over 72 weeks with lifestyle modifications.
• Superior efficacy compared to GLP-1 receptor agonists like semaglutide, with the SURMOUNT-1 trial reporting an average weight loss of 23.6 kg (23% of body weight)....